ARS Pharmaceuticals holder plans sale of 49K shares

ARS Pharmaceuticals, Inc. (SPRY) received a Rule 144 notice from stockholder Sarina Tanimoto covering a planned sale of up to 49,401 shares of common stock.

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. (SPRY) received a Rule 144 notice from stockholder Sarina Tanimoto covering a planned sale of up to 49,401 shares of common stock. The shares are tied to a stock option exercise for cash and are expected to be sold through Morgan Stanley Smith Barney LLC on or after 08/18/2026, with an indicated aggregate market value of $311,191.72 at the time of the notice.

Key Figures

Shares covered by Rule 144 notice: 49,401 shares Aggregate market value: $311,191.72 Proposed sale date: 08/18/2026 +2 more

5 metrics

Shares covered by Rule 144 notice 49,401 shares Common stock to be sold for the account of Sarina Tanimoto

Aggregate market value $311,191.72 Value referenced for the 49,401 shares in the Rule 144 notice

Proposed sale date 08/18/2026 Date listed for proposed sale of common shares

Security type Common stock Class of ARS Pharmaceuticals securities to be sold under Rule 144

Broker Morgan Stanley Smith Barney LLC Broker handling the potential sale of the Rule 144 shares

Key Terms

Rule 144, Stock Option Exercise, Executive Financial Services

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/18/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ARS Pharmaceuticals (SPRY) disclose?

The Form 144 discloses that Sarina Tanimoto plans to sell up to 49,401 SPRY common shares under Rule 144. The shares relate to a stock option exercise for cash, with an indicated aggregate market value of $311,191.72 at the time of the notice.

How many ARS Pharmaceuticals (SPRY) shares are covered by Sarina Tanimoto’s Rule 144 notice?

The notice covers up to 49,401 shares of ARS Pharmaceuticals common stock. These shares are associated with a stock option exercise and may be sold for cash on or after 08/18/2026 through Morgan Stanley Smith Barney LLC.

What is the estimated value of the SPRY shares in the Rule 144 notice?

The Rule 144 notice lists an aggregate market value of $311,191.72 for the 49,401 SPRY shares covered. This figure reflects the market value referenced in the notice at the time it was prepared, not a guaranteed sale price.

When are the ARS Pharmaceuticals (SPRY) shares expected to be sold under this Rule 144?

The planned sale date referenced is 08/18/2026. The notice indicates that up to 49,401 common shares related to a stock option exercise may be sold for cash on or after that date, subject to Rule 144 conditions.

Through which broker will the SPRY Rule 144 shares be sold?

The shares are expected to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s listed office is at 1 New York Plaza, 8th Floor, New York, NY 10004, and the trades relate to ARS Pharmaceuticals common stock on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 06:05 PM Accepted by SEC EDGAR 08/18/2026 - 06:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001951291
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARS PHARMACEUTICALS, INC.
SEC File Number	001-39756
Address of Issuer	11682 El Camino Real Suite 300 San Diego CALIFORNIA 92130
Phone	(858) 771-9307
Name of Person for Whose Account the Securities are To Be Sold	SARINA TANIMOTO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	49401	311191.72	99447343	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2026	Stock Option Exercise	Issuer			49401	08/18/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sarina Tanimoto
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)